Neuroprotection in Parkinson's disease facts and hopes /
Parkinson's disease (PD) is the second most common neurodegenerative disease worldwide. Behind the symptoms there is a complex pathological mechanism which leads to a dopaminergic cell loss in the substantia nigra pars compacta. Despite the strong efforts, curative treatment has not been found...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2020
|
| Sorozat: | JOURNAL OF NEURAL TRANSMISSION
127 |
| doi: | 10.1007/s00702-019-02115-8 |
| mtmt: | 31006931 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/17828 |
| LEADER | 01903nab a2200253 i 4500 | ||
|---|---|---|---|
| 001 | publ17828 | ||
| 005 | 20200626161632.0 | ||
| 008 | 200109s2020 hu o 0|| zxx d | ||
| 022 | |a 0300-9564 | ||
| 024 | 7 | |a 10.1007/s00702-019-02115-8 |2 doi | |
| 024 | 7 | |a 31006931 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a zxx | ||
| 100 | 1 | |a Salamon András | |
| 245 | 1 | 0 | |a Neuroprotection in Parkinson's disease |h [elektronikus dokumentum] : |b facts and hopes / |c Salamon András |
| 260 | |c 2020 | ||
| 300 | |a 821-829 | ||
| 490 | 0 | |a JOURNAL OF NEURAL TRANSMISSION |v 127 | |
| 520 | 3 | |a Parkinson's disease (PD) is the second most common neurodegenerative disease worldwide. Behind the symptoms there is a complex pathological mechanism which leads to a dopaminergic cell loss in the substantia nigra pars compacta. Despite the strong efforts, curative treatment has not been found yet. To prevent a further cell death, numerous molecules were tested in terms of neuroprotection in preclinical (in vitro, in vivo) and in clinical studies as well. The aim of this review article is to summarize our knowledge about the extensively tested neuroprotective agents (Search period: 1991-2019). We detail the underlying pathological mechanism and summarize the most important results of the completed animal and clinical trials. Although many positive results have been reported in the literature, there is still no evidence that any of them should be used in clinical practice (Cochrane analysis was performed). Therefore, further studies are needed to better understand the pathomechanism of PD and to find the optimal neuroprotective agent(s). | |
| 700 | 0 | 1 | |a Zádori Dénes |e aut |
| 700 | 0 | 1 | |a Szpisjak László |e aut |
| 700 | 0 | 1 | |a Klivényi Péter |e aut |
| 700 | 0 | 1 | |a Vécsei László |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/17828/1/SalamonA._NeuroprotectionInParkinsonSDis.pdf |z Dokumentum-elérés |